Introduction
============

Early and appropriate goal-directed fluid therapy is fundamental in acute resuscitation of critically ill patients \[[@B1],[@B2]\]; however, it is almost always associated with a certain degree of fluid overload (FO) \[[@B3],[@B4]\], which promotes tissue edema that could potentially contribute to progressive organ dysfunction \[[@B5],[@B6]\].

There is a growing amount of evidence supporting the relation between FO and unfavorable outcomes in critically ill patients. This has been demonstrated in general ICUs \[[@B7]\] and in specific clinical settings, such as acute lung injury/acute respiratory distress syndrome (ALI/ARDS) \[[@B8],[@B9]\], in patients undergoing abdominal surgery \[[@B10],[@B11]\], cardiac surgery \[[@B12]\] and in septic patients \[[@B13]\]. With regard to acute kidney injury (AKI) in particular, multiple pediatric studies have shown that a greater FO at the time of renal replacement therapy (RRT) is associated with higher mortality \[[@B14]-[@B16]\]. In a small study of 81 adult AKI patients who underwent RRT, a volume-related weight gain (VRWG) \>10%, used as a surrogate for FO, was similarly associated with poor outcomes \[[@B17]\]. An association between FO and higher mortality has also been shown in critically ill patients with less severe forms of AKI \[[@B18]-[@B21]\]. In this context, FO has emerged as a potential \'biomarker\' in critical illness, and it has been proposed that its prevention may be an important determinant of survival, particularly in AKI \[[@B3]\].

Oliguria is a common situation in the ICU and is considered an early and sensitive biomarker of renal injury because it may precede a creatinine-based diagnosis of AKI \[[@B22],[@B23]\]. Furthermore, in multicenter studies on critically ill patients with AKI, the presence of oliguria has been associated with higher mortality \[[@B20],[@B24]-[@B26]\]. Indeed, the evidence points out that both FO and oliguria are important predictors of mortality in critically ill patients. Fluid accumulation is a logical and expected complication of oliguric AKI due to impaired water and sodium excretion \[[@B20],[@B27]\]. It remains unclear whether their effects are independent of each other or if FO is merely in the causal pathway between oliguria and death. Interestingly, very few studies have adjusted for urine output in the analysis on FO and mortality. In 81 AKI patients requiring RRT, both oliguria and FO were independent predictors of mortality \[[@B17]\] and in a *post hoc*analysis of 306 AKI patients from the Fluid and Catheter Treatment Trial (FACTT), FO was shown to be independently associated with mortality both in oliguric and non-oliguric patients \[[@B19]\]. In a large multicenter European study \[[@B20]\] on critically ill patients with AKI, a positive fluid balance was an important factor associated with increased 60-day mortality, but there was no adjustment for urine volume or oliguria.

The aim of the present study is to evaluate the impact of both fluid balance and urine volume on outcomes and determine whether they behave as independent predictors of mortality in adult ICU patients with AKI.

Materials and methods
=====================

Study design and data collection
--------------------------------

We performed a secondary analysis of data from 601 patients enrolled in a prospective multicenter ICU cohort study of adult patients (age ≥18 years) admitted to 10 ICUs from September 2009 to April 2010 (NEFROlogia e Cura INTensiva (NEFROINT) Study), designed to describe the epidemiology of AKI in Italian ICUs \[[@B28]\]. Detailed methods of data collection have been previously described \[[@B29]\]. Collected data included demographics, anthropometrics, admission diagnosis, comorbidities, daily vital signs and laboratory data to calculate automatically the Acute Physiology and Chronic Health Evaluation II (APACHE II) \[[@B30]\], the Simplified Acute Physiology Score II (SAPS II) \[[@B31]\] and the Sequential Organ Failure Assessment (SOFA) \[[@B32]\] scores. RRT details and mortality were also reported. Furthermore, 24-hour urine output, worst 6-hour and worst 12-hour urine output, fluid balance and use of diuretics were recorded daily. Furosemide was the only diuretic used in all the centers. Fluid balance was calculated daily as the difference between fluid intake and fluid output. Fluid output included all body fluids, including urine and, if applicable, dialysis ultrafiltrate. This study was approved by the ethics committee of St. Bortolo Hospital, Vicenza, Italy. Because of the anonymous and non-interventional nature of the study, the ethics committees of the participating study centers (see list below) waived the need for informed consent.

Definitions
-----------

AKI was defined according to the renal SOFA score as a creatinine \>3.5 mg/dL or a urine output \<500 mL/day, as used by the Sepsis Occurrence in Acutely Ill Patients (SOAP) study investigators \[[@B20]\]. Patients who received RRT were assigned a renal SOFA score of 4, regardless of the serum creatinine or urine output. AKI was considered \'early\' if it occurred in the first two days of ICU admission and \'late\' if it occurred more than two days after ICU admission \[[@B20]\]. Oliguria was defined as a urine output of less than 500 mL/day. Mean fluid balance (MFB) and mean urine volume (MUV) were calculated as the arithmetic mean of the daily values during the patient\'s ICU stay. The SOFA score was expressed in two ways: total score and the score without the renal component (non-renal SOFA). For sensitivity analysis, we also defined AKI using the Risk, Injury, Failure, Loss of kidney function and End-stage kidney disease (RIFLE) consensus \[[@B33]\].

Statistical analysis
--------------------

Continuous variables were expressed as both mean ± SD and as median (IQR) and compared between any two groups (for example, AKI versus non-AKI, survivors versus non-survivors, early versus late AKI and so on), using the t-test or Mann-Whitney U test, as appropriate. Normality of distribution was evaluated by visual inspection of histograms and by the Kolmogorov Smirnov test. Categorical variables are expressed as number of cases and proportion and compared with the Mantel-Haenszel Chi-square test or the Fisher exact test.

To evaluate the influence of MFB and MUV on the survival time of AKI patients, exploratory univariate analysis for several variables was first performed to identify possible confounders associated with 28-day mortality. A multivariable Cox regression analysis was then performed using a forward stepwise selection method, criteria for entry 0.05 and for removal 0.10. The assumption of proportional hazards was checked graphically using log(-log(survival probability)) plots and was found appropriate. Variables considered for multivariable analysis were age, gender, co-morbid disease, sepsis, non-renal SOFA, and MFB, as were used in a previous study \[[@B20]\], with the addition of MUV and diuretic use. Age, sepsis and diuretic use were all significant on univariate analysis. APACHE II, SAPS II, and total and non-renal SOFA scores were also significant on univariate analysis, but the strongest association with mortality was seen with non-renal SOFA, and this was used in all multivariable models. We tested for collinearity among all variables. From the Cox model, hazard ratio (HR) and 95% CIs were generated. We also performed a number of sensitivity analyses. First, since MFB and MUV were found to be collinear, we repeated the analysis using an interaction term MFB\*MUV. Second, we also expressed urine output as the presence of oliguria anytime during the ICU stay and the duration of oliguria (defined as the proportion of ICU days complicated by oliguria) as an alternate representation of urine volume in the models. Third, diuretic use was also expressed as duration of diuretic use (defined by the proportion of ICU days in which diuretics were used). The 28-day survival by timing of AKI, oliguria and diuretic use were additionally evaluated graphically using the Kaplan-Meier product limit survival plot. All statistical analysis was performed using the SPSS 19.0 (SPSS Inc, Chicago, IL, USA) software package, with a two-sided *P*value \<0.05 considered as statistically significant.

Results
=======

Study population
----------------

Of the 601 patients enrolled in the NEFROINT study \[[@B28]\], 25 were excluded because of the presence of end-stage renal disease on chronic RRT and three other patients were excluded because of incomplete data on fluid balance and urine output, leaving 573 patients for analysis. Characteristics of the entire cohort are shown in Additional file [1](#S1){ref-type="supplementary-material"}, Table S1. The mean age was 63.0 ± 17.3 years and 59.5% were men. All-cause 28-day mortality was 21.8% and mean ICU length of stay was 10.1 ± 12.0 days. Of these patients, 132 (23%) developed AKI.

Acute kidney injury
-------------------

AKI patients were older, more likely to be diabetic and to have sepsis or a cardiovascular diagnosis at ICU admission and higher illness severity scores than non-AKI \[see Additional file [1](#S1){ref-type="supplementary-material"}, Table S1\]. MFB was higher (0.7 ± 1.2 versus 0.5 ± 1.1 L/day; *P*= 0.008) and MUV was lower (1.8 ± 1.1 versus 2.6 ± 1.3 L/day; *P*\<0.001) in the AKI group. Diuretics were used more commonly on AKI patients and for a larger proportion of ICU days (Table [1](#T1){ref-type="table"}). Mortality was higher among AKI patients (50% versus 13.4%; *P*\<0.001) and ICU stay was longer.

###### 

Fluid balance, urine volume and diuretic use by presence or absence of AKI.

  ----------------------------------------------------------------------------------------------------------------
                                    All (number = 573)    AKI (number = 132)    Non-AKI (number = 441)   *P*
  --------------------------------- --------------------- --------------------- ------------------------ ---------
  Mean fluid balance/24hours (L)    0.52 ± 1.11\          0.74 ± 1.16\          0.45 ± 1.09\             0.008
                                    0.40 (0.04 to 0.97)   0.48 (0.02 to 1.26)   0.38 (-0.05 to 0.86)     

  Mean urine volume/24hours (L)     2.43 ± 1.31\          1.81 ± 1.08\          2.62 ± 1.32\             \<0.001
                                    2.39 (1.66 to 3.06)   1.88 (0.87 to 2.73)   2.54 (1.86 to 3.11)      

  Use of diuretics (%)              365 (63.7%)           102 (77.3%)           263 (59.6%)              \<0.001

  Duration of diuretic use (days)   5.3 ± 8.5\            8.3 ± 11.3\           4.4 ± 7.2\               \<0.001
                                    2 (0 to7)             4 (1 to 10)           2 (0 to 6)               

  \% ICU days with diuretics        43.2 ± 39.6%\         51.0 ± 37.6%\         (40.9 ± 39.9%)\          0.010
                                    42.9 (0 to 80.5%)     51.9 (8.7 to 87.5%)   38.5 (0 to 78.4%)        
  ----------------------------------------------------------------------------------------------------------------

AKI, acute kidney injury.

AKI patient characteristics according to outcome are shown in Table [2](#T2){ref-type="table"}. Non-surviving AKI patients were older, had higher illness severity scores and were more likely to be septic. The MFB was higher (1.3 ± 1.2 versus 0.2 ± 0.7 L/day; *P*\<0.001) and the MUV was lower (1.3 ± 0.9 versus 2.3 ± 1.0 L/day; *P*\<0.001) among non-survivors. Oliguria was also more common in non-survivors (83.3% versus 54.5%; *P*= 0.001) and persisted for a larger proportion of the ICU stay (35.5 ± 34.5% versus 13.6 ± 21.9%; *P*\<0.001).

###### 

AKI patient characteristics by outcome.

  ------------------------------------------------------------------------------------------------------------------------------------
                                            All AKI (number = 132)   Survivors (number = 66)   Non-Survivors (number = 66)   *P*
  ----------------------------------------- ------------------------ ------------------------- ----------------------------- ---------
  Male gender                               84 (63.6%)               43 (34.8%)                41 (62.1%)                    0.86

  Age (years)                               66.3 ± 14.1\             63.1 ± 15.6\              69.5 ± 11.7\                  0.015
                                            68.5 (38 to 57.5)        64 (52.8 to 76)           74 (61 to 78.3)               

  **ICU Admission**                                                                                                          

  SAPS II                                   50.0 ± 14.5\             46.3 ± 13.5\              53.7 ±14.6\                   0.001
                                            48 (38 to 57.5)          42 (37 to 52.8)           51.5 (43.8 to 61.3)           

  SOFA                                      8.0 ± 4.1\               6.8 ± 3.6\                9.2 ± 4.3\                    0.002
                                            7 (5 to 11)              7 (4 to 9.3)              8.5 (6 to 12)                 

  Non-renal SOFA                            6.6 ± 3.5\               5.4 ± 2.9\                7.8 ± 3.6\                    \<0.001
                                            6 (4 to 9)               5 (3 to 7)                7 (5 to 11)                   

  APACHE II                                 22.3 ± 8.4\              20.3 ± 7.7\               24.4 ± 8.6\                   0.006
                                            21 (16 to 28)            19 (15 to 25.3)           24 (16.8 to 31)               

  Vasoactive therapy                        56 (42.4%)               21 (31.8%)                35 (53.0%)                    0.022

  Mechanical ventilation                    96 (72.7%)               44 (66.7%)                52 (78.8%)                    0.17

  Serum creatinine (mg/dL)                  2.3 ± 2.0\               2.3 ± 2.0\                2.4 ± 2.1\                    0.99
                                            1.45 (0.9 to 3.2)        1.4 (0.9 to 3.1)          1.5 (0.8 to 3.3)              

  **Comorbid diseases**                                                                                                      

  Diabetes                                  41 (31.1%)               20 (30.3%)                21 (31.8%)                    1

  Cardiovascular                            66 (50.0%)               31 (47.0%)                35 (53.0%)                    0.60

  Hypertension                              67 (50.8%)               29 (43.9%)                38 (57.6%)                    0.16

  Chronic kidney disease                    19 (14.4%)               10 (15.2%)                9 (13.6%)                     1

  Metastatic carcinoma                      4 (3.0%)                 3 (4.5%)                  1 (1.5%)                      0.62

  Hematologic malignancy                    6 (4.5%)                 2 (3.0%)                  4 (6.1%)                      0.68

  **Category of ICU admission diagnosis**                                                                                    

  Respiratory                               44 (33.3%)               20 (30.3%)                24 (36.4%)                    0.58

  Neurologic                                15 (11.4%)               9 (13.6%)                 6 (9.1%)                      0.59

  Trauma                                    8 (6.1%)                 5 (7.6%)                  3 (4.5%)                      0.72

  Cardiovascular                            25 (18.9%)               12 (18.2%)                13 (19.7%)                    1

  Sepsis                                    15 (11.4%)               6 (9.1%)                  9 (13.6%)                     0.59

  **ICU course**                                                                                                             

  Sepsis                                    61 (46.2%)               23 (34.8%)                38 (57.6%)                    0.014

  Early AKI (%)                             83 (62.9%)               39 (59.1%)                44 (66.7%)                    0.47

  Mean fluid balance/24hours (L)            0.74 ± 1.16\             0.17 ± 0.72\              1.31 ± 1.24\                  \<0.001
                                            0.48 (0.02 to 1.26)      0.02 (-0.17 to 0.48)      1.09 (0.49 to 1.85)           

  Oliguria                                  91 (68.9%)               36 (54.5%)                55 (83.3%)                    0.001

  Duration of oliguria (days)               2.8 ± 5.9\               1.6 ± 4.0\                4.0 ± 7.2\                    \<0.001
                                            1 (0 to 3)               1 (0 to 1)                2 (1 to 4)                    

  \% of ICU days with oliguria              24.6 ± 30.8%\            13.6 ± 21.9%\             35.5 ± 34.5\                  \<0.001
                                            11.9% (0 to 37.1%)       2.8% (0 to 20.7%)         25% (6.7 to 62.0%)            

  Mean urine volume/24hour(L)               1.81 ± 1.08\             2.35 ± 0.98\              1.28 ± 0.90\                  \<0.001
                                            1.88 (0.87 to 2.73)      2.49 (1.61 to 3.12)       1.22 (0.55 to 1.96)           

  Use of diuretics (%)                      102 (77.3%)              55 (83.3%)                47 (71.2%)                    0.15

  Duration of diuretic use (days)           8.3 ± 11.3\              10.3 ± 13.5\              6.4 ± 8.3\                    0.11
                                            4 (1 to 10.8)            4.5 (1 to 13)             3 (0 to 10)                   

  \% of ICU days receiving diuretics        51.0 ± 37.6\             56.2 ± 36.7%\             45.9 ± 38.1%\                 0.11
                                            51.9% (8.7 to 87.5%)     55.6% (20 to 93.0%)       46.9% (0 to 82.6%)            

  **Outcomes**                                                                                                               

  RRT                                       67 (50.8%)               31 (47.0%)                36 (54.5%)                    0.49

  Duration of RRT (days)(% of ICU days)     3.2 ± 6.9\               2.2 ± 4.3\                4.1 ± 8.7\                    0.14
                                            1 (1 to 3)               0 (0 to 3)                1.5 (0 to 5)                  

  \% of ICU days on RRT                     23.3 ± 31.3%\            15.4 ± 24.1%\             31.1 ± 35.6%\                 0.03
                                            3.9% (0 to 45.2%)        0% (0 to 21.6%)           6.7% (0 to 66.7%)             

  RRT free days                             12.1 ± 13.9\             15.1 ±17.1\               9.1 ± 8.8\                    0.06
                                            8 (3 to 16.8)            9 (3 to 23.3)             6.5 (2.8 to 13)               

  Length of ICU stay (days)                 15.3 ± 16.3\             17.4 ± 18.7\              13.2 ±13.2\                   0.45
                                            10 (5 to 20)             11.5 (5 to 24)            9 (4 to 19.3)                 
  ------------------------------------------------------------------------------------------------------------------------------------

AKI, acute kidney injury; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment; APACHE II, Acute Physiology and Chronic Health Evaluation II; RRT, renal replacement therapy.

Early AKI was present in 83 patients (62.9% of the AKI group) and was associated with higher illness severity scores, lower MUV (1.6 ± 1.1 versus 2.2 ± 0.9 L/day; *P*\<0.001), a larger proportion of days of oliguria (32.3% versus 11.5%, *P*\<0.001) and fewer RRT-free days, but a shorter ICU stay than late AKI \[see Additional file [1](#S1){ref-type="supplementary-material"}, Table S2\]. The MFB, the proportion of days with diuretics and the mortality were not different between the groups.

As expected, oliguric patients had a higher MFB (0.9 ± 1.3 versus 0.4 ± 1.0 L/day; *P*\<0.001), tended to receive diuretics more often (73.6% versus 62.7%; *P*= 0.06), had higher mortality (60.4% versus 14.4%; *P*\<0.001) and longer ICU stay (15.5 ± 15.8 versus 9.3 ± 10.9; *P*\<0.001) than non-oliguric patients.

Mean fluid balance, mean urine volume and mortality
---------------------------------------------------

In general, non-survivor AKI patients had significantly higher MFB compared to survivors (Figure [1](#F1){ref-type="fig"}). When analyzing the subgroups separately by AKI timing, the presence of oliguria and the use of diuretics, the same results were observed. The MUV was significantly lower among non-survivors overall, and in most of the subgroups, except in non-oliguric patients. Figure [2](#F2){ref-type="fig"} demonstrates the pattern of cumulative fluid balance among survivors and non-survivors in the first seven days in the ICU. Non-survivors consistently had higher mean cumulative fluid balance throughout the ICU stay and the magnitude of the difference between the groups increased with each additional day.

![**Mean fluid balance (A) and mean urine volume (B) in survivors and non-survivors**. \**P*\<0.05; \*\**P*\<0.001. AKI, acute kidney injury.](cc12484-1){#F1}

![**Cumulative fluid balance in survivors and non-survivors in the first seven days of ICU stay (mean ± SEM)**. \**P*=0.015; \*\**P*\<0.01. SEM, standard error of the mean.](cc12484-2){#F2}

The 28-day survival was significantly better among non-oliguric patients (Figure [3](#F3){ref-type="fig"}; *P*\<0.044) and in patients treated with diuretics (Figure [4](#F4){ref-type="fig"}; *P*= 0.001). The 28-day survival was similar between early and late AKI (not shown, *P*= 0.16 on log rank test).

![**Survival curve for 28-day mortality by the presence or absence of oliguria in the ICU**.](cc12484-3){#F3}

![**Survival curve for 28-day mortality by the use or non-use of diuretics in the ICU**.](cc12484-4){#F4}

On multivariate Cox regression analysis (Table [3](#T3){ref-type="table"}), both MFB and MUV were independent predictors of 28-day mortality (MFB, adjusted HR 1.67, 95%CI 1.33 to 2.09 per L/day; *P*\<0.001 and MUV, adjusted HR 0.47, 95%CI 0.33 to 0.67 per L/day; *P*\<0.001, Model 1). Interestingly, the use of diuretics appeared to be associated with a lower risk of death in both unadjusted and adjusted analysis (adjusted HR 0.25, 95%CI 0.12 to 0.52; *P*\<0.001). Collinearity was observed between MFB and MUV, and we performed a second model including the interaction between the two (MFB\*MUV). In this model, the interaction term was significant; the effect of MFB was somewhat attenuated, while the effect of MUV was accentuated. Of interest, higher non-renal SOFA scores were significantly associated with increased mortality on univariate analysis (HR 1.18, 95CI% 1.10 to 1.27; *P*\<0.001), but this was no longer significant on multivariable analysis (HR 1.04, 95CI% 0.96 to 1.14; *P*= 0.35).

###### 

Cox regression analysis for 28-day mortality.

                               Unadjusted            Adjusted                                                          
  ---------------------------- --------------------- ---------- --------------------- --------- ---------------------- ---------
  Mean fluid balance (L/day)   1.99 (1.68 to 2.36)   \<0.001    1.67 (1.33 to 2.09)   \<0.001   1.33 (1.002 to 1.77)   0.0048
  Mean urine volume (L/day)    0.38 (0.29 to 0.51)   \<0.001    0.47 (0.33 to 0.67)   \<0.001   0.33 (0.21 to 0.52)    \<0.001
  Diuretic use                 0.40 (0.23 to 0.70)   0.001      0.25 (0.12 to 0.52)   \<0.001   0.26 (0.13 to 0.53)    \<0.001
  Diabetes                     1.16 (0.68 to 1.98)   0.58       2.16 (1.09 to 4.26)   0.027     2.08 (1.06 to 4.08)    0.033
  Hypertension                 1.76 (1.06 to 2.94)   0.03       2.18 (1.12 to 4.22)   0.021     2.17 (1.12 to 4.24)    0.023
  MFB\*MUV                     \-                    \-         \-                    \-        1.53 (1.16-2.01)       0.003

Variables considered for model 1 included age, gender, co-morbid diseases (diabetes, hypertension and cardiovascular disease), non-renal SOFA, sepsis, mean fluid balance, mean urine volume and diuretic use. In model 2, MFB\*MUV (interaction term between MFB and MUV) was also included. Only significant variables are shown in the table. HR, hazard ratio; MFB, mean fluid balance; MUV, mean urine volume.

In terms of sensitivity analyses \[see Additional file [1](#S1){ref-type="supplementary-material"}, Table S3\], qualitatively similar results were seen when MUV was alternatively expressed as presence of oliguria (adjusted HR 1.86, 95%CI 1.50 to 2.32 for MFB, and adjusted HR 1.35, 95%CI 0.67 to 2.71 for oliguria) or duration of oliguria (adjusted HR 1.72, 95%CI 1.37 to 2.15 for MFB, and adjusted HR 1.01, 95%CI 1.003 to 1.02 for %ICU days with oliguria), and when diuretic usage was expressed as duration of diuretics (adjusted HR 1.73, 95%CI 1.38 to 2.18 for MFB and adjusted HR 0.99, 95%CI 0.98 to 0.99 for %ICU days on diuretics). Furthermore, results were also similar when AKI was defined using RIFLE criteria (*n*= 378 AKI patients; crude mortality 28.8%). The adjusted HR for MFB was 1.51, 95%CI 1.31 to 1.74 L/day; *P*\<0.001 and for MUV was 0.48, 95%CI 0.38 to 0.62 L/day; *P*\<0.001 in this sensitivity analysis (Table [4](#T4){ref-type="table"}).

###### 

Sensitivity analysis considering presence of AKI according to RIFLE classification.

                                   Unadjusted            Adjusted                         
  -------------------------------- --------------------- ---------- --------------------- ---------
  Mean fluid balance/24hours (L)   1.74 (1.56 to 1.95)   \<0.001    1.51 (1.31 to 1.74)   \<0.001
  Mean urine volume/24hours (L)    0.39 (0.32 to 0.48)   \<0.001    0.48 (0.38 to 0.62)   \<0.001
  Diuretic use                     0.34 (0.22 to 0.52)   \<0.001    0.31 (0.19 to 0.51)   \<0.001
  Diabetes                         1.36 (0.88 to 2.10)   0.17       1.75 (1.08 to 2.85)   0.023

Variables considered for the model included age, gender, co-morbid diseases (diabetes, hypertension and cardiovascular disease), non-renal SOFA, sepsis, mean fluid balance, mean urine volume and diuretic use. Only significant variables are shown in the table. AKI, acute kidney injury; HR, hazard ratio; RIFLE, Risk of renal dysfunction, Injury to the kidney, Failure of kidney function, Loss of kidney function and End-stage kidney disease.

Discussion
==========

Using data from a multicenter ICU cohort \[[@B28]\], we examined the influence of fluid balance and urine volume on outcomes among critically ill patients with AKI. The key findings of this study are: first, AKI patients had higher MFB, lower MUV, and a higher mortality than non-AKI patients; second, MFB was significantly higher in non-survivors in all AKI patients, and consistently higher across various subgroups (early and late AKI, oliguric and non-oliguric, use and non-use of diuretics, Figure [1](#F1){ref-type="fig"}); third, MUV was lower in non-survivors in all subgroups, except non-oliguric patients; finally, both MFB and MUV were significantly associated with increased 28-day mortality in AKI patients, and their interaction was significant as well.

Our results are consistent with prior studies on critically ill patients, both without and with AKI. In non-AKI studies, a positive fluid balance was strongly associated with increased mortality and other unfavorable outcomes in some subgroups of ICU patients, including worse lung function, longer duration of mechanical ventilation, increased post-operative complications and longer ICU stay \[[@B7]-[@B13]\]. Among adult AKI patients in particular, Van Biesen *et al.*\[[@B21]\] showed that additional fluid loading not only failed to improve renal function, but was also associated with worsening of respiratory function. The Program to Improve Care in Acute Renal Disease (PICARD) group \[[@B18]\] concluded that fluid weight gain \>10% in AKI patients was associated with higher mortality and that the increase in mortality rate was proportional to the degree of fluid accumulation. In a study with 1,120 ICU patients with AKI, the authors showed that the MFB was an independent predictor of mortality on multivariate analysis (adjusted HR 1.21, 95%CI 1.13 to 1.28; *P*\<0.001) \[[@B20]\]. However, these three studies did not adjust for urine volume in their models.

An important finding in the present study is that fluid balance and urine volume were both strong and significant predictors of mortality, even accounting for their interaction. We reproduced the analysis performed in AKI patients from a multicenter European ICU cohort \[[@B20]\] and extended it by adding the variable urine volume to the analysis. Our findings confirmed the association of both FO (adjusted HR per L/day of MFB 1.67, 95%CI 1.33 to 2.09; *P*\<0.001) and reduced urine volume (adjusted HR per L/day of MUV 0.47, 95%CI 0.33 to 0.67; *P*\<0.001) with adverse outcomes. Qualitatively similar findings were obtained even when the urine volume was expressed as the presence of oliguria or duration of oliguria, implying that FO is not merely an intermediate in the pathway between lower urine output and mortality. This relation is not well-explored in the literature. To our knowledge, only two adult AKI studies have adjusted for urine output in their analysis of FO and outcomes. In a cohort of 81 adult critically ill patients with severe AKI requiring RRT, the authors examined the effect of oliguria, VRWG used as a measure of FO, sepsis and APACHE II score in the multivariate model \[[@B17]\]. Both oliguria and VRWG ≥10% were predictors of 30-day mortality (adjusted odds ratio (OR) 3.04, 95%CI 1.10 to 8.36 and adjusted OR 2.71, 95%CI 1.05 to 6.99, respectively). In the aforementioned FACTT study, the association between fluid balance and mortality was significant in patients both with oliguria (HR per L/day of MFB 1.77, 95%CI 1.27 to 2.45) and without oliguria (HR per L/day of MFB 1.61, 95%CI 1.27 to 2.45) during the initial seven days after randomization \[[@B19]\]. Our findings are consistent with these studies. Furthermore, we observed that the interaction between fluid balance and urine volume was statistically significant, and still MFB and MUV individually remained predictors of 28-day mortality.

The association between oliguria and worse outcomes in AKI patients is well recognized \[[@B4],[@B22]\]. In our study, the survival of non-oliguric patients was significantly better when compared to oliguric patients (Figure [3](#F3){ref-type="fig"}), but in both groups non-survivors had significantly higher MFB (Figure [1](#F1){ref-type="fig"}). Similarly to other authors \[[@B20],[@B25]\], we did not find significant differences in mortality between patients who developed early or late AKI (not shown, *P*= 0.16 on log rank test) but again, non-survivors in both groups presented significantly higher MFB and lower MUV.

An interesting finding in the present study is that the use of diuretics was inversely associated with mortality, and this effect persisted after adjustment for MFB and MUV (adjusted HR 0.25, 95%CI 0.12 to 0.52), suggesting that the diuretic in itself may exert a protective effect. This differs from the FACTT study, in which post-AKI furosemide use had a protective effect on 60-day mortality on univariate analysis, but not when adjusted for fluid balance \[[@B19]\]. The role of diuretics in AKI remains controversial. While three meta-analyses \[[@B34]-[@B36]\] have demonstrated a lack of association between diuretics and mortality, only two of the included studies enrolled ICU patients. Two observational studies in ICU settings showed conflicting results. The PICARD Study Group concluded that diuretic use increased the risk of death or non-recovery of renal function (OR 1.77, 95%CI 1.14 to 2.76) \[[@B37]\]. In contrast, the Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) investigators did not find a significant association between diuretic use and mortality (adjusted OR 1.21, 95%CI 0.96 to 1.5) \[[@B38]\]. Loop diuretics have effects that could be potentially beneficial in preventing or minimizing the severity of AKI. They reduce the oxygen demand and prevent hypoxic damage, and furosemide has been shown to improve renal hemodynamics, attenuate ischemic-related renal angiogenesis and reduce ischemic-induced apoptosis in animal models \[[@B39]-[@B41]\]. A pilot phase II randomized, blinded, placebo-controlled trial comparing furosemide to placebo in ICU patients with early AKI is in progress \[[@B42]\]; this study aims to compare the efficacy and safety of furosemide versus placebo on the progression of AKI severity and fluid balance. The results of this trial will help us to understand better the role of diuretics in AKI in the critical care setting.

Our study has important strengths including its multicenter design that contributes to reduce practice bias. The depth of data collection permitted the exploration of the effects of duration of oliguria and diuretic use, which confirmed the results of the main analysis. Our study also extends this continuous association of fluid balance, decreased urine volume and death to critically ill adults meeting the consensus definition for AKI (RIFLE). However, we recognize some limitations. Because of the observational nature of the study, we cannot establish a causal relationship between MFB, MUV and mortality. The modest sample size precluded extensive subgroup analysis and may have resulted in underestimation of the impact of known risk factors, such as SOFA score, on multivariable analysis. We did not collect data on actual diuretic dose, but the proportion of ICU days in which diuretics were used can be considered a reasonable surrogate. It is possible that the type of fluid (that is, colloid versus crystalloid, parenteral versus enteral), aside from the volume, influences outcomes. Unfortunately, this information was not available in our own study or in previous investigations on FO \[[@B9],[@B13]\]. We believe this is an important issue that needs to be clarified with future studies. Nevertheless, our findings are consistent across the multiple sensitivity analyses performed and the association between fluid balance, urine volume and mortality appears robust.

Conclusions
===========

In summary, both fluid balance and urine volume were found to be independent predictors of mortality in adult critically ill patients with AKI. Of interest, diuretic use appeared to be independently associated with better survival in this study. The results of an ongoing phase II randomized controlled trial on diuretics in early AKI will help clarify this issue.

Key messages
============

• In this multicenter observational study in ICU patients with AKI, non-survivors presented higher MFB (1.3 ± 1.2 versus 0.2 ± 0.7 L/day; *P*\<0.001) and lower MUV (1.3 ± 0.9 versus 2.3 ± 1.0 L/day). Both higher fluid balance and a lower urine volume were shown to be independent predictors of 28-day mortality in this AKI population.

• The use of diuretics was associated with better survival.
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